Episode 200 - October 23, 2026

The 200th episode of Biotech Hangout examines the current biotech landscape, characterized by significant market volatility and a shift toward asset-centric business models. Technical trading patterns and the influence of platform funds often decouple stock prices from fundamental value, as seen in recent fluctuations for Moderna and Abivax. Industry leaders emphasize the necessity of authentic communication, noting that direct engagement on social media helps humanize the sector for the public. Former Silence Therapeutics CEO Ali Mortazavi reflects on the decade-long journey of RNAi development, underscoring that successful drug commercialization relies heavily on disciplined clinical operations rather than just platform hype. Despite a challenging short-term market, the sector remains fundamentally robust, driven by innovation in oncology and neuroscience, with a growing emphasis on cost-effective, lean organizational structures to navigate future patent cliffs and economic uncertainty.